Our Role
Seeger Weiss attorneys played a key role in this case, helping negotiate an efficient and positive settlement for investor plaintiffs. Partner Dave Buchanan developed a slate of experts to overcome Pfizer’s early science challenges to the case. Founding partner Chris Seeger led the plaintiff’s presentation and examinations during the seven-day Daubert hearing.
Following pre-trial motion practice and ensuing appeals, Pfizer settled the case, resulting in a $486 million cash settlement fund for the class of aggrieved investors.
Pfizer Misrepresentation of Medication
Pfizer allegedly misled shareholders about risks associated with two prescription medications: arthritis medication, Celebrex, and painkiller, Bextra. Evidence indicated that Pfizer recognized the potential cardiovascular risks of these medications but deliberately concealed these risks from shareholders. Plaintiffs alleged that these omissions violated federal securities laws, defrauding a class of investors.
